Mizuho Wants "to Get More Constructive" on Valeant Pharma (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Valeant Pharma (VRX) AdCom on Brodalumab Begins
July 19, 2016 8:10 AM EDTValeant Pharma (NYSE: VRX) FDA advisory committee meeting for Brodalumab is starting now. Click here to access the webcast.
For the Brodalumab briefing docs, click here.
Shares of Valeant are lower in early trading Tuesday.
... MoreValeant (VRX) Scripts Plunge Amid 4-Day Week
July 18, 2016 10:16 AM EDTRBC Capital analyst Douglas Miehm notes Valeant Pharmaceuticals (NYSE: VRX) scripts fell following a four-day week (July 4th): Derm NRx were down 29.4% WoW and ophth NRx were down 19.1%.
NRx Derm products down 29.4% WoW. For the week ending July 8th, new derm scripts (NRx) were down 29.4% vs. up 0.9% the prior week due to a four-day week... More
